Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;327 (6 September), doi:10.1136/bmj.327.7414.0-g
| The first 150 words of the full text of this article appear below. |
"Fortune assists the bold," wrote Virgil, thinking of the Trojan wars not of medicine. But there is room for boldness in medicine, and I see examples in this BMJ.
The Global Initiative on Chronic Obstructive Lung Diseasea pretentiously named outfit that must have slavered over its acronym GOLD and which is backed by the National Institutes of Health and the World Health Organizationwarns against using opioids in managing patients with dyspnoea and chronic obstructive pulmonary disease (p 523). We all know that opioids are respiratory depressants and that such patients have almost no respiratory reserve. Yet some experienced doctors believe that morphine can help patients with refractory dyspnoea. A bold group from Australia has now conducted an adequately powered crossover trial of oral morphine against placebo in patients with refractory dyspnoea in whom the underlying aetiology is maximally treated (p 523). The morphine produced important
Richard Smith, editor
rsmith@bmj.com
Read all Rapid Responses